Skip to content

Effect of Unani formulation in Dark Spots on face.

Efficacy of Rewandchini with Asl as Zimad in Kalaf (Melasma) - A Randomized Controlled Trial.

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/07/044251
Enrollment
37
Registered
2022-07-22
Start date
Unknown
Completion date
Unknown
Last updated
2022-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L814- Other melanin hyperpigmentation Health Condition 2: L814- Other melanin hyperpigmentation

Interventions

Intervention1: Efficacy of Unani single drug Rewandchini: Safoof of Rewandchini 2-3 gms with half teaspoon of asl prepared as zimad for local application in clinical trail on cases of kalaf melasma o

Sponsors

Goverrment Unani Medical College And Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Clinical patients of Kalaf (Melasma) 2 Patients of either sex 3 Patients between 18-50yrs of age 4 Patients with Fitzpatrick skin type III- type V 5 Patient m-MASI score up to 3 (Moderate/Marked) in darkness and 6 Duration of Melasma 7 Willingness to participate in the study and follow the instructions

Exclusion criteria

Exclusion criteria: 1 Patients with any systemic illness and malignancies 2 Patients on contraceptive pills 3 Skin sensitivity 4 Severe cases of Melasma (m-MASI score >50%) 5 Pregnancy/ Lactating women 6 Hormonal replacement therapy 7 Topical bleaching agents for at least 1month or chemical peeling or laser at least 4months before the start of the study

Design outcomes

Primary

MeasureTime frame
improvement in kalaf melasma as per mMASI score and PGA scoreTimepoint: improvement in kalaf melasma as per mMASI score and PGA score on 7th 14th 21st 28th 35th 42nd day

Secondary

MeasureTime frame
NilTimepoint: Nil

Countries

India

Contacts

Public ContactDr Wasima Swaleha

Government Unani Medical College and Hospital

drnusrathfarooque@rediffmail.com7022317892

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026